Is it Beneficial to Treat Patients Presenting Three Weeks or Longer after the Onset of Sudden Sensorineural Hearing Loss?

J Int Adv Otol

Department of Otolaryngology-Head and Neck Surgery, Shaare Zedek Medical Center, Hebrew University Medical School, Jerusalem, Israel.

Published: December 2020

Objectives: The accepted treatment for idiopathic sudden sensorineural hearing loss (ISSNHL) consists of oral or intratympanic steroids. The time from onset to treatment is considered as an important prognostic factor, although there is no clear cutoff point when treatment is no longer beneficial. This study aimed to assess the efficacy of treatment with oral or intratympanic steroids and carbogen, in patients presenting 21 days or later after the onset of hearing loss.

Materials And Methods: A total of 895 patients with ISSNHL was seen in our center between 2010 and 2018. The study cohort included 103 patients treated with oral or intratympanic steroids or both with carbogen 21 days or longer after experiencing hearing loss. Retrospective analysis of files and audiometry was conducted, and pre- and post-treatment audiograms were compared. Improvement was defined by SRT (≥15 dB improvement), discrimination (≥15% improvement), or 15 dB improvement at specific frequencies (250-500, 4000-6000 Hz).

Results: Hearing improvement, according to the study definition, was seen in 22.3% (23/103) of patients within the time period of the treatment. All the 23 patients had functional hearing after treatment and 16 of them returned to their baseline or normal hearing. While the time from onset of ISSNHL to treatment varied, most patients demonstrating improvement were treated 21-30 days after onset.

Conclusion: In this patient cohort treated late for sudden sensorineural hearing loss (SSNHL), a small but significant number of patients improved during the time of treatment. Although the lack of a control group makes it difficult to prove that the improvement resulted from the treatment, we recommend not to rule out treatment systematically in patients presenting late after ISSNHL. Additional prospective studies are warranted.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901470PMC
http://dx.doi.org/10.5152/iao.2020.8489DOI Listing

Publication Analysis

Top Keywords

patients presenting
12
sudden sensorineural
12
sensorineural hearing
12
hearing loss
12
oral intratympanic
12
intratympanic steroids
12
treatment
10
patients
9
hearing
8
time onset
8

Similar Publications

Purpose The present study aimed to clarify the distribution pattern of carcinoma associated fibroblasts (CAFs) across pancreatic ductal adenocarcinoma (PDAC) and its prognostic prediction value. Methods Data of two cohorts were retrospectively collected from consecutive patients who underwent primary pancreatic resection from January 2015 to December 2017. We used tumor specimens to screen out the most suitable markers for the spatial distribution analysis for CAFs subpopulations.

View Article and Find Full Text PDF

A Neurocysticercosis Case from Timor-Leste, A Previously Unidentified Region of Human Taeniasis Endemicity.

Am J Trop Med Hyg

January 2025

Department of Environmental Biology & Medical Parasitology, Hanyang University College of Medicine, Seoul, Republic of Korea.

Neurocysticercosis, a central nervous system infection caused by the zoonotic parasite Taenia solium, is a leading cause of acquired epilepsy worldwide. It is common in areas with extensive pig farming and pork consumption. This report presents an unusual case of neurocysticercosis in a 28-year-old male from Timor-Leste, a region of nonendemicity for human cases of Taenia solium.

View Article and Find Full Text PDF

How I Treat Higher-Risk MDS.

Blood

January 2025

H. Lee Moffitt Cancer Center, Tampa, Florida, United States.

Myelodysplastic syndromes/neoplasms (MDS) are a widely heterogenous group of myeloid malignancies characterized by morphologic dysplasia, a defective hematopoiesis, and recurrent genetic abnormalities. The original and revised International Prognostic Scoring Systems (IPSS) have been used to risk-stratify patients with MDS to guide treatment strategies. In higher-risk MDS, the therapeutic approach is geared toward delaying leukemic transformation and prolonging survival.

View Article and Find Full Text PDF

Variations in the TP53 and KRAS genes indicate a particularly adverse prognosis in relapsed pediatric T-ALL. We hypothesized that these variations might be subclonally present at disease onset and contribute to relapse risk. To test this, we examined two cohorts of children diagnosed with T-ALL: one with 81 patients who relapsed and 79 matched non-relapsing controls, and another with 226 consecutive patients, 30 of whom relapsed.

View Article and Find Full Text PDF

Background: With increasing adoption of remote clinical trials in digital mental health, identifying cost-effective and time-efficient recruitment methodologies is crucial for the success of such trials. Evidence on whether web-based recruitment methods are more effective than traditional methods such as newspapers, media, or flyers is inconsistent. Here we present insights from our experience recruiting tertiary education students for a digital mental health artificial intelligence-driven adaptive trial-Vibe Up.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!